SAN DIEGO, June 2, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today announced the launch of its estrogen receptor (ER) status testing on CTCs that will be performed at the Company’s CLIA-certified and CAP-accredited laboratory.
Help employers find you! Check out all the jobs and post your resume.
